Logo image of HALO

HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis

USA - NASDAQ:HALO - US40637H1095 - Common Stock

65.77 USD
+0.44 (+0.67%)
Last: 10/14/2025, 9:41:56 AM
Fundamental Rating

8

HALO gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. HALO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. HALO is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make HALO a good candidate for value and growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

HALO had positive earnings in the past year.
HALO had a positive operating cash flow in the past year.
Each year in the past 5 years HALO has been profitable.
Each year in the past 5 years HALO had a positive operating cash flow.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

The Return On Assets of HALO (27.13%) is better than 97.76% of its industry peers.
Looking at the Return On Equity, with a value of 167.48%, HALO belongs to the top of the industry, outperforming 99.63% of the companies in the same industry.
HALO has a Return On Invested Capital of 28.55%. This is amongst the best in the industry. HALO outperforms 98.88% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for HALO is above the industry average of 15.49%.
The 3 year average ROIC (17.81%) for HALO is below the current ROIC(28.55%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 27.13%
ROE 167.48%
ROIC 28.55%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

The Profit Margin of HALO (47.28%) is better than 98.88% of its industry peers.
HALO's Profit Margin has declined in the last couple of years.
HALO has a Operating Margin of 57.92%. This is amongst the best in the industry. HALO outperforms 99.81% of its industry peers.
HALO's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 84.20%, HALO belongs to the top of the industry, outperforming 87.13% of the companies in the same industry.
In the last couple of years the Gross Margin of HALO has grown nicely.
Industry RankSector Rank
OM 57.92%
PM (TTM) 47.28%
GM 84.2%
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
HALO has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, HALO has less shares outstanding
Compared to 1 year ago, HALO has an improved debt to assets ratio.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 5.16 indicates that HALO is not in any danger for bankruptcy at the moment.
HALO's Altman-Z score of 5.16 is fine compared to the rest of the industry. HALO outperforms 75.00% of its industry peers.
The Debt to FCF ratio of HALO is 2.79, which is a good value as it means it would take HALO, 2.79 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.79, HALO belongs to the best of the industry, outperforming 94.03% of the companies in the same industry.
HALO has a Debt/Equity ratio of 4.54. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of HALO (4.54) is worse than 81.90% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.54
Debt/FCF 2.79
Altman-Z 5.16
ROIC/WACC3.31
WACC8.63%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 8.36 indicates that HALO has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.36, HALO is doing good in the industry, outperforming 74.44% of the companies in the same industry.
HALO has a Quick Ratio of 7.01. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
HALO has a better Quick ratio (7.01) than 69.59% of its industry peers.
Industry RankSector Rank
Current Ratio 8.36
Quick Ratio 7.01
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

8

3. Growth

3.1 Past

HALO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.41%, which is quite impressive.
HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 30.12% yearly.
HALO shows a strong growth in Revenue. In the last year, the Revenue has grown by 34.97%.
Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 38.95% on average per year.
EPS 1Y (TTM)58.41%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%69.23%
Revenue 1Y (TTM)34.97%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%40.79%

3.2 Future

The Earnings Per Share is expected to grow by 18.27% on average over the next years. This is quite good.
HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.85% yearly.
EPS Next Y48.66%
EPS Next 2Y38.6%
EPS Next 3Y33.13%
EPS Next 5Y18.27%
Revenue Next Year31.57%
Revenue Next 2Y27.61%
Revenue Next 3Y24.03%
Revenue Next 5Y13.85%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8 10

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 12.70 indicates a correct valuation of HALO.
Based on the Price/Earnings ratio, HALO is valued cheaply inside the industry as 96.83% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.34. HALO is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 8.09, the valuation of HALO can be described as very reasonable.
Based on the Price/Forward Earnings ratio, HALO is valued cheaper than 98.13% of the companies in the same industry.
HALO is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.86, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.7
Fwd PE 8.09
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaply inside the industry as 96.27% of the companies are valued more expensively.
96.64% of the companies in the same industry are more expensive than HALO, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 14.23
EV/EBITDA 10.62
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HALO has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as HALO's earnings are expected to grow with 33.13% in the coming years.
PEG (NY)0.26
PEG (5Y)N/A
EPS Next 2Y38.6%
EPS Next 3Y33.13%

More info and screens

0

5. Dividend

5.1 Amount

HALO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (10/14/2025, 9:41:56 AM)

65.77

+0.44 (+0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)10-29 2025-10-29/amc
Inst Owners102.63%
Inst Owner Change-0.04%
Ins Owners0.85%
Ins Owner Change0.1%
Market Cap7.69B
Analysts75
Price Target76.12 (15.74%)
Short Float %10.19%
Short Ratio5.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.03%
Min EPS beat(2)14.79%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)16.87%
Min EPS beat(4)6.64%
Max EPS beat(4)26.79%
EPS beat(8)7
Avg EPS beat(8)12.25%
EPS beat(12)10
Avg EPS beat(12)12.69%
EPS beat(16)13
Avg EPS beat(16)10.59%
Revenue beat(2)2
Avg Revenue beat(2)12.25%
Min Revenue beat(2)11.69%
Max Revenue beat(2)12.81%
Revenue beat(4)4
Avg Revenue beat(4)9.78%
Min Revenue beat(4)1.36%
Max Revenue beat(4)13.28%
Revenue beat(8)5
Avg Revenue beat(8)5.19%
Revenue beat(12)7
Avg Revenue beat(12)3.36%
Revenue beat(16)9
Avg Revenue beat(16)2.8%
PT rev (1m)4.37%
PT rev (3m)5.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.57%
EPS NY rev (1m)0.47%
EPS NY rev (3m)12.09%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)2.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.65%
Valuation
Industry RankSector Rank
PE 12.7
Fwd PE 8.09
P/S 6.53
P/FCF 14.23
P/OCF 14.04
P/B 23.12
P/tB N/A
EV/EBITDA 10.62
EPS(TTM)5.18
EY7.88%
EPS(NY)8.13
Fwd EY12.35%
FCF(TTM)4.62
FCFY7.03%
OCF(TTM)4.68
OCFY7.12%
SpS10.08
BVpS2.84
TBVpS-3.85
PEG (NY)0.26
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 27.13%
ROE 167.48%
ROCE 35.56%
ROIC 28.55%
ROICexc 39.96%
ROICexgc 93.15%
OM 57.92%
PM (TTM) 47.28%
GM 84.2%
FCFM 45.87%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexcg growth 3Y-1.13%
ROICexcg growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 4.54
Debt/FCF 2.79
Debt/EBITDA 1.97
Cap/Depr 8.67%
Cap/Sales 0.6%
Interest Coverage 250
Cash Conversion 71.66%
Profit Quality 97.02%
Current Ratio 8.36
Quick Ratio 7.01
Altman-Z 5.16
F-Score8
WACC8.63%
ROIC/WACC3.31
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)58.41%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%69.23%
EPS Next Y48.66%
EPS Next 2Y38.6%
EPS Next 3Y33.13%
EPS Next 5Y18.27%
Revenue 1Y (TTM)34.97%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%40.79%
Revenue Next Year31.57%
Revenue Next 2Y27.61%
Revenue Next 3Y24.03%
Revenue Next 5Y13.85%
EBIT growth 1Y68.72%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.62%
EBIT Next 3Y39.07%
EBIT Next 5Y15.57%
FCF growth 1Y84.66%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y79.07%
OCF growth 3Y16.96%
OCF growth 5YN/A